International News
New Test Aids Clinicians in Accelerating Tuberculosis Diagnosis
Roche has recently launched the cobas MTB-RIF/INH test to detect resistance to antibiotics within tuberculosis DNA. A complete mycobacteria test menu provides the flexibility to detect a combination of tuberculosis, drug-resistant tuberculosis, and nontuberculous mycobacteria infections from a single patient sample. This provides important information for patient care decisions.
The fully automated cobas 6800/8800 systems offer the fastest time to results with the highest throughput and the longest walk-away time available among automated molecular platforms, providing laboratories with improved operating efficiency and the flexibility to adapt to changing testing demands. The cobas MTB test enables the detection of mycobacterium tuberculosis complex (MTBC) DNA, while the cobas MAI test enables the direct detection and differentiation of mycobacterium avium and mycobacterium intracellulare DNA in symptomatic patients.
Michael Heuer
CEO
Roche Diagnostics
“With the addition of cobas MTB-RIF/INH to the mycobacteria test menu, we are able to equip laboratories with flexible, sensitive solutions to best help them diagnose tuberculosis, which is difficult to detect. This menu approach not only aids healthcare providers in addressing the global health challenge that tuberculosis presents, but also provides clinicians the valuable information they need to properly diagnose these respiratory infections to speed treatment and reduce the spread of infection.”
